ArticleApplied microbiology and biotechnology2017
Novel insights into biosynthesis and uptake of rhamnolipids and their precursors.
Article in Applied microbiology and biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 121 citations in OpenAlex.
- Enhancing acetate-based biosurfactant production by Pseudomonas putida KT2440 through fermentation optimization.Microbial cell factories · 2026Article
- Metabolomic-Metabolite Profiling: Progressive Insight and Biochemical Pathway in Crude Oil Waste Sludge Co-Composting Bioremediation.Metabolites · 2026Article
- Acetate as alternative carbon source for production of mono- and di-rhamnolipids in Pseudomonas putida KT2440.Microbial cell factories · 2026Article
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Enhanced rhamnolipid production in Pseudomonas aeruginosa 8D by systematic genetic engineering.Microbial cell factories · 2026Article
- Heterologous rhamnolipid biosynthesis byApplied and environmental microbiology · 2025Article
- Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.Microbial biotechnology · 2025Review
- Molecular and genomic insights into multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa causing burn wound infections in Bangladesh.Scientific reports · 2025Article
- Investigating the wettability of neem oil nanoemulsion as a green pesticide on leaf surfaces - optimizing formulation, assessing stability, and enhancing wettability.RSC advances · 2025Article
- Bioprocess exploitation of microaerobic auto-induction using the example of rhamnolipid biosynthesis in Pseudomonas putida KT2440.Journal of biological engineering · 2025Article
- Genetically engineeredFrontiers in microbiology · 2025Article
- Prospects and challenges regarding biosurfactants in advancing the petroleum industry.Frontiers in bioengineering and biotechnology · 2025Review
- Article
- Synthesis of di-rhamnolipids by the avirulent, mono-rhamnolipid producing strain Pseudomonas aeruginosa ATCC 9027.Biotechnology letters · 2024Article
- Novel Insights into Cr(VI)-Induced Rhamnolipid Production and Gene Expression inJournal of microbiology and biotechnology · 2024Article
- Optimizing Systems for Robust Heterologous Production of Biosurfactants Rhamnolipid and Lyso-Ornithine Lipid inMolecules (Basel, Switzerland) · 2024Article
- Application of Biosurfactants in Medical Sciences.Molecules (Basel, Switzerland) · 2024Review
- Metabolic insights from mass spectrometry imaging of biofilms: A perspective from model microorganisms.Methods (San Diego, Calif.) · 2024Review
- Unlocking the potential of biosurfactants: Innovations in metabolic and genetic engineering for sustainable industrial and environmental solutions.Biotechnology notes (Amsterdam, Netherlands) · 2024Review
- Biosynthesis and Gene Regulation of Rhamnolipid Congeners.Current microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human pathogenic bacterium Pseudomonas aeruginosa produces rhamnolipids, glycolipids with functions for bacterial motility, biofilm formation, and uptake of hydrophobic substrates. Rhamnolipids represent a chemically heterogeneous group of secondary metabolites composed of one or two rhamnose molecules linked to one or mostly two 3-hydroxyfatty acids of various chain lengths. The biosynthetic pathway involves rhamnosyltransferase I encoded by the rhlAB operon, which synthesizes 3-(3-hydroxyalkanoyloxy)alkanoic acids (HAAs) followed by their coupling to one rhamnose moiety. The resulting mono-rhamnolipids are converted to di-rhamnolipids in a third reaction catalyzed by the rhamnosyltransferase II RhlC. However, the mechanism behind the biosynthesis of rhamnolipids containing only a single fatty acid is still unknown. To understand the role of proteins involved in rhamnolipid biosynthesis the heterologous expression of rhl-genes in non-pathogenic Pseudomonas putida KT2440 strains was used in this study to circumvent the complex quorum sensing regulation in P. aeruginosa. Our results reveal that RhlA and RhlB are independently involved in rhamnolipid biosynthesis and not in the form of a RhlAB heterodimer complex as it has been previously postulated. Furthermore, we demonstrate that mono-rhamnolipids provided extracellularly as well as HAAs as their precursors are generally taken up into the cell and are subsequently converted to di-rhamnolipids by P. putida and the native host P. aeruginosa. Finally, our results throw light on the biosynthesis of rhamnolipids containing one fatty acid, which occurs by hydrolyzation of typical rhamnolipids containing two fatty acids, valuable for the production of designer rhamnolipids with desired physicochemical properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.